Toggle Main Menu Toggle Search

Open Access padlockePrints

Soluble E-cadherin: An early marker of severity in acute pancreatitis

Lookup NU author(s): Richard Charnley, Dr Avinash Sewpaul, Jeremy French, Dr Tien Kheng Khoo, Emeritus Professor John Kirby

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background/Aims. At present, there is no simple test for predicting severity in acute pancreatitis. We investigated the use of an assay of soluble E-cadherin (sE-cadherin). Methods. Concentrations of sE-cadherin, from 19 patients with mild acute pancreatitis, 7 patients with severe acute pancreatitis, 11 patients with other acute gastrointestinal pathologies, and 12 healthy subjects were measured using a commercially available sandwich ELISA kit based on two monoclonal antibodies specific to the extracellular fragment of human E-cadherin. Measurements were made at 12 hours or less from onset of pain and also at 24 and 48 hours after onset of pain. Results. Mean (standard deviation) concentration of sE-cadherin in patients with severe acute pancreatitis at < 12 hours was 17780 ng/mL (7853), significantly higher than that of healthy volunteers 5180 ng/mL (1350), P =.0039, patients with other gastrointestinal pathologies 7358 ng/mL (6655), P =.0073, and also significantly higher than that of patients with mild pancreatitis, 7332 ng/mL (2843), P =.0019. Discussion. Serum sE-cadherin could be an early (within 12 hours) objective marker of severity in acute pancreatitis. This molecule warrants further investigation in the form of a large multicentre trial.


Publication metadata

Author(s): Charnley R, Sewpaul A, French J, Khoo T, Kernohan M, Kirby J

Publication type: Article

Publication status: Published

Journal: HPB Surgery

Year: 2009

Pages: article ID: 397375

ISSN (print): 0894-8569

ISSN (electronic): 1607-8462

Publisher: Hindawi Publishing Corporation

URL: http://dx.doi.org/10.1155/2009/397375

DOI: 10.1155/2009/397375


Altmetrics

Altmetrics provided by Altmetric


Share